39 citations
,
April 2019 in “The journal of immunology/The Journal of immunology” Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
3 citations
,
November 2024 in “Egyptian Journal of Medical Human Genetics” SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.
1 citations
,
January 2023 in “Indian Dermatology Online Journal” Skin and nail changes are common in patients with blood cancers undergoing chemotherapy, affecting their quality of life.
April 2026 in “Metabolites” Chronic skin diseases and metabolic syndrome are linked by shared inflammation pathways.
January 2025 in “PLoS ONE” ING5 is crucial for stem cell maintenance and preventing certain cancers.
September 2023 in “International journal of molecular sciences” Targeting lipid metabolism can help treat advanced, resistant cancers.
5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
February 2024 in “Buletin Veteriner Udayana” The dog with severe hair loss and itching improved after treatment for ehrlichiosis and demodicosis.
40 citations
,
October 2017 in “Acta Dermato Venereologica” Understanding patients' views on their illness can help improve their disease management.
54 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings”
June 2023 in “International Journal of Research in Medical Sciences” Two brothers from Bangladesh were diagnosed with X-linked adrenoleukodystrophy, showing neurological and adrenal symptoms.
September 2022 in “Frontiers in genetics” A Chinese male with a new genetic mutation has a skin condition and severe urinary issues, with treatments having mixed success.
1 citations
,
January 2015 in “The Journal of Dermatology” Genetic testing is crucial for diagnosing and managing non-Herlitz junctional epidermolysis bullosa.
April 2021 in “BMJ Case Reports” Accurate diagnosis of pseudolymphomatous folliculitis is crucial to avoid mistaking it for more serious conditions.
November 2017 in “British Journal of Dermatology” The electronic version of the Dermatology Life Quality Index is as effective as the paper version, with most patients preferring it.
July 2024 in “Journal of Investigative Dermatology” Pediatric patients with dystrophic epidermolysis bullosa face more hospital admissions, procedures, and complications than others.
1 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Careful histologic examination is crucial to differentiate types of bullous lesions in cutaneous lupus erythematosus.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
33 citations
,
October 2006 in “European Journal of Immunology” The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.
April 2017 in “Journal of Investigative Dermatology” The study found a link between the severity of Lichen Planopilaris seen by doctors and the details seen under a microscope, and created a new way to measure this severity.
2 citations
,
August 2004 in “Veterinary Dermatology” A dog with a hereditary skin condition causing blisters and hair loss survived for a year.
January 2009 in “Elsevier eBooks” Low level laser therapy may help with hair loss.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
10 citations
,
August 2021 in “EMBO Reports” The Bcl-2 protein is important for keeping hair follicle stem cells working and preventing hair loss.
March 2025 in “International Journal For Multidisciplinary Research” Computational techniques can improve drug development for treating certain conditions.
36 citations
,
July 2007 in “Journal of Investigative Dermatology” Certain HLA class II alleles increase or decrease the risk of alopecia areata.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
October 2025 in “Pediatric Dermatology” A 16-year-old boy's facial condition improved with doxycycline, suggesting an immune response to hair follicle damage.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.